Literature DB >> 8616915

Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene.

P Zoldhelyi1, J McNatt, X M Xu, D Loose-Mitchell, R S Meidell, F J Clubb, L M Buja, J T Willerson, K K Wu.   

Abstract

BACKGROUND: Prostacyclin is an important vasoprotective molecule. It inhibits platelet aggregation, monocyte interaction with endothelium, and smooth muscle cell lipid accumulation. Vascular cyclooxygenase-1 (COX-1) is the rate-limiting step in prostacyclin synthesis. The objective of this study was to determine whether adenovirus-mediated transfer of COX-1 could restore COX-1 activity, augment prostacyclin synthesis, and prevent thrombus formation in a porcine carotid angioplasty model. METHODS AND
RESULTS: Human COX-1 cDNA driven by a cytomegalovirus promoter was constructed into a replication-defective adenovirus 5 vector by homologous recombination. Recombinant adenovirus without a foreign gene (Ad-RR) and buffer were included as controls. Recombinant Ad-LacZ was used for marking the transfected cells in vivo. In the in vitro experiments, cultured human endothelial cells (ECs) and porcine arterial smooth muscle cells (SMCs) were incubated with Ad-COX-1 for 2 hours and 6-keto-PGF(1 alpha) level and the transgene expression were determined 72 hours after infection. In the in vivo experiments, recombinant adenoviruses were directly instilled into angioplasty-injured porcine carotid arteries for 30 minutes. Cyclic flow changes were monitored for 10 days and thrombus formation was examined histologically thereafter. Transgene expression and prostaglandin I2 (PGI2) synthesis by the injured arteries were determined. Cultured ECs infected with Ad-COX-1 produced a fivefold to eightfold increase in PGI2, and the transgene expression in cultured porcine SMCs was demonstrated by Northern analysis. Direct administration of Ad-COX-1 at a dose of 3 x 10(10) pfu completely inhibited carotid cyclic flow changes and thrombus formation accompanied by a fourfold increase in PGI2 synthesis by the injured arteries 10 days after infection, whereas Ad-COX-1 at a lower dose, 5 x 10(9) pfu, had no antithrombotic effects when compared with Ad-RR vector and buffer controls.
CONCLUSIONS: Adenovirus-mediated transfer of COX-1 to angioplasty-injured carotid arteries was efficacious in augmenting PGI2 synthesis and was associated with an inhibition of thrombosis when a relatively high titer of adenovirus was instilled.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616915     DOI: 10.1161/01.cir.93.1.10

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Antithrombotic strategies in gene therapy.

Authors:  K M Channon; B H Annex
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

3.  Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.

Authors:  P Zoldhelyi; Z Q Chen; H S Shelat; J M McNatt; J T Willerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 4.  Vascular effects of prostacyclin: does activation of PPARδ play a role?

Authors:  Zvonimir S Katusic; Anantha V Santhanam; Tongrong He
Journal:  Trends Pharmacol Sci       Date:  2012-06-23       Impact factor: 14.819

5.  Neuroprotective role of haptoglobin after intracerebral hemorrhage.

Authors:  Xiurong Zhao; Shen Song; Guanghua Sun; Roger Strong; Jie Zhang; James C Grotta; Jaroslaw Aronowski
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

6.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

Review 7.  Gene transfer to the vasculature: historical perspective and implication for future research objectives.

Authors:  Sarah J George; Andrew H Baker
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

Review 8.  Gene therapy for the prevention of vein graft disease.

Authors:  Kevin W Southerland; Sarah B Frazier; Dawn E Bowles; Carmelo A Milano; Christopher D Kontos
Journal:  Transl Res       Date:  2012-12-27       Impact factor: 7.012

Review 9.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

10.  Gene therapy for atherosclerosis and atherosclerosis-related diseases.

Authors:  T Pakkanen; S Ylä-Herttuala
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.